BioSpace News Archive

CERo Therapeutics Holdings, Inc., announces it is presenting preclinical data on its lead product candidate CER-1236 at the Stanford Drug Discovery Symposium, which is being held April 29-30, 2024 in Palo Alto, Calif.

ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO) today announced the initiation of a Phase 2 investigator-sponsored trial (“IST”) of neoadjuvant radiation and evorpacept, a next-generation CD47 blocker, in combination KEYTRUDA® (pembrolizumab) in patients with previously untreated and early-stage locally advanced, resectable, human papillomavirus-mediated oropharyngeal cancer (“HPVOC”).

Kamari Pharma announced the appointment of John Doux, MD, MBA, to the company’s Board of Directors.

AEYE Health, the leading company for AI retinal imaging and diagnostics, is thrilled to announce that it received the first ever FDA clearance for a fully autonomous AI that diagnoses referable diabetic retinopathy from retinal images obtained by a handheld camera.

BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (“BioHarvest” or the “Company”), a biotechnology company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the fourth quarter and full year ended December 31, 2023.

LivaNova PLC, a market-leading medical technology company, announced Ahmet Tezel, Ph.D., will join the Company as Chief Innovation Officer, effective May 13, 2024.

BioMed X, a German biomedical research institute, announces the start of a new research project in partnership with Merck at its site in Heidelberg, Germany.

Sphere Fluidics announced the appointment of Dale Levitzke as CEO with immediate effect, as Dr. Frank F. Craig, current CEO and co-founder, announces his retirement.

Cingulate Inc. announced that longstanding Cingulate investor and board member Peter J. Werth will join Cingulate Chairman and CEO Shane J. Schaffer in a live Benzinga All Access event on Friday May 3, 2024, at 12:10 p.m. EST.

Zymeworks Inc., a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, announced that management will participate in the following upcoming investor conferences.